• Log In
Model AD
  • Home
  • Cores
    • Administrative Core
    • IU/JAX/PITT Bioinformatics and Data Management Core (BDMC)
    • IU/JAX/PITT Disease Modeling Project
    • IU/JAX/PITT Preclinical Testing Core
    • UCI Functional Genomics, Bioinformatics and Data Management Core (FGBDMC)
    • UCI Disease Model Development and Phenotyping (DMP)
    • UCI Neuroimaging and Neurovascular Core (NIVC)
  • External Advisory Board
  • Resources
  • Collaborators
  • News and Publications
Select Page

STOP-AD portal: Selecting the optimal pharmaceutical for preclinical drug testing in Alzheimer’s disease

by abbottmj | May 15, 2023 | Uncategorized | 0 comments

STOP-AD portal: Selecting the optimal pharmaceutical for preclinical drug testing in Alzheimer’s disease
Quinney SK, Murugesh K, Oblak A, Onos KD, Sasner M, Greenwood AK, Woo KH, Sukoff Rizzo SJ, Territo PR

https://pubmed.ncbi.nlm.nih.gov/37157089/

Recent Posts

  • Meeting report of the annual workshop on Principles and Techniques for Improving Preclinical to Clinical Translation in Alzheimer’s Disease research
  • STOP-AD portal: Selecting the optimal pharmaceutical for preclinical drug testing in Alzheimer’s disease
  • Differential splicing of neuronal genes in a Trem2*R47H mouse model mimics alterations associated with Alzheimer’s disease

Quicklinks

AD Knowledge Portal

MODEL-AD Explorer

Models Available

STOP-AD Compound Submission Portal

AD Neuroimaging Initiative (ADNI)

AD Preclinical Efficacy Database (AlzPED)

National Institute on Aging

Contact us:

IU/JAX/PITT

UCI

The IU/JAX/UCI MODEL-AD Consortium was established with funding from The National Institute on Aging (U54 AG054345-01 and AG054349). Aging studies are also supported by the Nathan Shock Center of Excellence in the Basic Biology of Aging (NIH P30 AG0380770). Contact us: ModelAD@iupui.edu